Compare TRDA & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | EAF |
|---|---|---|
| Founded | 2016 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.6M | 429.4M |
| IPO Year | 2021 | 2018 |
| Metric | TRDA | EAF |
|---|---|---|
| Price | $11.99 | $6.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $20.00 | $11.75 |
| AVG Volume (30 Days) | 190.2K | ★ 276.0K |
| Earning Date | 05-07-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $25,421,000.00 | ★ $504,134,000.00 |
| Revenue This Year | $39.97 | $4.25 |
| Revenue Next Year | $50.80 | $12.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $0.55 |
| 52 Week High | $13.99 | $20.32 |
| Indicator | TRDA | EAF |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 43.09 |
| Support Level | $10.78 | $5.90 |
| Resistance Level | $12.56 | $7.47 |
| Average True Range (ATR) | 0.78 | 0.55 |
| MACD | -0.10 | 0.33 |
| Stochastic Oscillator | 30.58 | 45.36 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.